Nateraの空売り状況は、投資家がNateraの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Natera (NASDAQ:NTRA) 株価情報, 空売り情報

Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Natera Inc

13 analysts have shared their evaluations of Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $158.69, a high estimate of $200.00, and a low estimate of $135.00. Marking an increase of 16.03%, the current average surpasses the previous average price target of $136.77. 
<img src="https://www.benzinga.com/files/images/story/2024/1731952822_0_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Natera among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$176.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$157.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Natera. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Natera compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Natera's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Natera's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NTRA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Natera analyst ratings.</a>
<h2>Discovering Natera: A Closer Look</h2>
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
<h3>Natera: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Natera's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 63.9% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Natera's net margin is impressive, surpassing industry averages. With a net margin of -7.18%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Natera's ROE excels beyond industry benchmarks, reaching -3.68%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Natera's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.03%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Natera's debt-to-equity ratio is below the industry average at 0.54, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

NTRA

Analyst Expectations For Natera's Future

Piper Sandler analyst David Westenberg maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $150 to $200.

News

Price Target

Piper Sandler Maintains Overweight on Natera, Raises Price Target to $200

Morgan Stanley analyst Tejas Savant maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $132 to $176.

Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $176

<h3>Gainers</h3>
<ul>
<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) shares rose 22.7% to $2.7 during Wednesday's pre-market session. The market value of their outstanding shares is at $331.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock rose 19.74% to $2.46. The market value of their outstanding shares is at $31.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares increased by 18.48% to $2.5. The market value of their outstanding shares is at $29.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) shares rose 16.66% to $157.64. The company's market cap stands at $19.4 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 15.62% to $0.78. The market value of their outstanding shares is at $11.6 million. The company's, Q3 earnings came out yesterday. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) stock increased by 12.61% to $8.66. The company's market cap stands at $286.3 million. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares decreased by 85.6% to $0.39 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.5 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock decreased by 72.24% to $0.44. The market value of their outstanding shares is at $2.5 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock fell 23.4% to $0.05. The company's market cap stands at $2.9 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares declined by 20.03% to $0.21. The market value of their outstanding shares is at $32.1 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares declined by 20.0% to $2.6. The company's market cap stands at $22.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 17.6% to $0.51. The market value of their outstanding shares is at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CERO

CLDI

ENSC

GCTK

GOVX

KAPA

LXEO

MRSN

SYRS

VRPX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) reported better-than-expected third-quarter financial results and issued FY24 revenue guidance <a href="https://www.benzinga.com/quote/NTRA/earnings">above estimates on Tuesday</a>.
Natera reported a quarterly loss of 26 cents per share, which beat the analyst consensus estimate of a loss of 58 cents per share . The company reported quarterly sales of $439.800 million which beat the analyst consensus estimate of $361.450 million.
&#8220;Our strong performance in the third quarter reflects our unwavering dedication to the patients we serve and the passion of our employees in each of our business areas,&#8221; said Steve Chapman, chief executive officer of Natera. &#8220;We grew volumes, revenue, gross margin, and cash flow in what continues to be a transformational year for Natera.&#8221;
Natera said it sees FY24 revenue of $1.61 billion to $1.64 billion, versus market estimates of $1.518 billion.
Natera shares jumped 22.3% to trade at $165.31 on Wednesday.
Several analysts made changes to their price targets for Natera following the release of quarterly results.
<ul>
<li>Baird analyst Catherine Ramsey maintained Natera with an Outperform and raised the price target from $120 to $160.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6013eddd879cba0001e6f199/kyle-mikson">Canaccord Genuity analyst Kyle Mikson </a>maintained the stock with a Buy and raised the price target from $150 to $165.</li>
<li>JP Morgan analyst Julia Qin maintained Natera with an Overweight and raised the price target from $135 to $160.</li>
<li>Craig-Hallum analyst Alexander Nowak maintained the stock with a Buy and increased the price target from $121 to $157.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e5d05312fc7510001ab2cc4/dan-brennan">TD Cowen analyst Dan Brennan </a>maintained Natera with a Buy and boosted the price target from $155 to $175.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41939161/how-to-earn-500-a-month-from-helmerich-payne-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Helmerich &amp; Payne Stock Ahead Of Q4 Earnings</a></li>
</ul>

Earnings

Markets

Trading Ideas

Natera Analysts Increase Their Forecasts Following Upbeat Results

TD Cowen analyst Dan Brennan maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Buy and raises the price target from $155 to $175.

TD Cowen Maintains Buy on Natera, Raises Price Target to $175

Wall Street saw a modest rebound on Wednesday, spurred by an in-line inflation report that reinforced expectations for a December rate cut. The U.S. dollar continued to gain strength, buoyed by potential tariff tailwinds under <a href="https://www.benzinga.com/topic/donald-trump">the new Trump administration.</a>
Bitcoin again captured headlines as it surged past $93,000, lifting its market capitalization to $1.8 trillion and fueling a wave of enthusiasm across crypto markets, with Dogecoin up over 12%.
The Consumer Price Index met expectations in October, with the annual headline rate increasing to 2.6% and the core <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41938762/october-inflation-rate-rises-to-2-6-as-expected-december-interest-rate-cut-remains-uncertain">rate steady at 3.3%. </a>
The report alleviated concerns over a potential rate pause in December, driving market odds for a 25-basis-point cut from 58% to 82%, as per the CME FedWatch tool. Treasury yields eased slightly in response to the report.
By midday in New York, all major U.S. equity indices were in slightly positive territory, although with the tech-heavy Nasdaq 100 underperforming. Leading sectors included consumer discretionary and real estate, while utilities and health care lagged.
In political developments, U.S. Sen. John Thune (R-SD) was elected as the new majority leader in a secret ballot.
The U.S. dollar, tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), hit its highest level since November 2023, marking a fresh one-year high.
Gold dipped 0.6%, on track for a fourth consecutive loss.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,084.11</td>
<td>0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,401.00</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,002.13</td>
<td>0.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,073.91</td>
<td>0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.3% to $598.42.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.4% to $440.97.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) flattened at $513.06.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.3% higher to $238.1.</li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 1%. The&nbsp;Utilities Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.3%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
<ul>
<li>Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) rallied over 18% after the company announced a joint venture launch with Volkswagen valued at&nbsp;up to $5.8 billion.</li>
<li>Albemarle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) rose 6% after Berenberg raised the stock price target from $81 to $102.</li>
<li>Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) fell 2.4% after the company announced a 4% cut to its global workforce.</li>
</ul>
Stocks reacting to earnings report were: 
<ul>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), up 12%</li>
<li>Occidental Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), down 1.2%</li>
<li>Flutter Entertainment plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), up 6.5%</li>
<li>Natera Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), up 22%,</li>
<li>CAVA Group Inc., up 6.5%</li>
<li>CyberArk Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>), down 0.3%</li>
<li>Loar Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>), down 6%</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/11/41940984/disney-bulls-await-earnings-for-streaming-growth-bob-iger-successor-clues">Disney Bulls Await Earnings For Streaming Growth, Bob Iger Successor Clues</a></li>
</ul>
Photo via Shutterstock.

Broad U.S. Equity ETFs

Econ #s

Federal Reserve

ETFs

CYBR

SPDR Dow Jones Industrial Average ETF Trust

FLUT

LOAR

RIVN

SPOT

PowerShares DB US Dollar Index Bullish Fund

Select Sector SPDR-Consumer Discretionary

Stocks Edge Higher, Dollar Hits 1-Year Peak, Bitcoin Soars To $93,000: What's Driving Markets Wednesday?

Craig-Hallum analyst Alexander Nowak maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Buy and raises the price target from $121 to $157.

Craig-Hallum Maintains Buy on Natera, Raises Price Target to $157

U.S. stocks were mixed, with the Nasdaq Composite falling around 50 points on Wednesday.
Shares of Paymentus Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) rose sharply in today's session after the company reported better-than-expected third-quarter financial results and issued FY24 revenue guidance <a href="https://www.benzinga.com/quote/PAY/earnings">above estimates</a>.
Also, Baird maintained an Outperform rating on the stock and raised its price target from $25 to $36.
Paymentus Holdings shares jumped 23.8% to $32.97 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Jet.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares surged 56% to $10.36. Jet.AI's board approved $2 million share repurchase program through 2025 and announced withdrawal of S-1 registration.</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) shares jumped 46.8% to $92.19 after the company reported better-than-expected third-quarter adjusted EPS results and raised its FY24 sales guidance.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 36% to $19.93 after the company reported better-than-expected quarterly financial results. The company also announced a multi-launch agreement with a confidential commercial satellite constellation operator and was awarded a federal defense contract worth up to $8 million.</li>
<li>Paragon 28, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNA#NYSE">FNA</a>) rose 34.8% to $10.20 following third-quarter results.</li>
<li>The Honest Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNST#NASDAQ">HNST</a>) gained 28.3% to $6.16 after the company reported better-than-expected quarterly sales results.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) gained 27.5% to $4.4000 following third-quarter results.</li>
<li>Altus Power, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) gained 21.5% to $3.7788 after the company reported better-than-expected quarterly EPS and sales.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) gained 20% to $162.15 after the company reported better-than-expected third-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) gained 15.3% to $12.19 after the company announced a joint venture launch with Volkswagen for a total deal size worth up to $5.8 billion.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) rose 15.3% to $7.28.</li>
<li>Tower Semiconductor Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) gained 11.8% to $48.22 after the company reported better-than-expected quarterly financial results.</li>
<li>James Hardie Industries plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) rose 9.9% to $34.93.</li>
<li>CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) gained 9.1% to $158.26 after the company reported better-than-expected third-quarter financial results and raised its FY24 net new restaurant openings outlook and same sales growth.</li>
<li>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) rose 7.1% to $110.09.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) gained 6.9% to $448.39 following third-quarter earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41939709/jim-cramer-says-intuitive-surgical-is-a-fantastic-expensive-company">Jim Cramer Says Intuitive Surgical Is A &#8216;Fantastic, Expensive Company&#8217;</a></li>
</ul>

Intraday Update

AMPS

CAVA

DAVE

HNST

JBLU

JTAI

ORGO

RKLB

TSEM

Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday

JP Morgan analyst Julia Qin maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $135 to $160.

JP Morgan Maintains Overweight on Natera, Raises Price Target to $160

Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Buy and raises the price target from $150 to $165.

Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $165

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler boosted the price target for Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) from $67 to $94. Piper Sandler analyst Clarke Jeffries maintained a Neutral rating. Shopify shares closed at $108.92 on Tuesday. <a href="https://www.benzinga.com/quote/SHOP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut the price target for Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) from $5 to $4. Needham analyst Serge Belanger maintained a Buy rating. Heron Therapeutics shares closed at $1.28 on Tuesday. <a href="https://www.benzinga.com/quote/HRTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) price target from $132 to $148. Goldman Sachs analyst Stephen Laszczyk maintained a Buy rating. Live Nation shares settled at $129.67 on Tuesday. <a href="https://www.benzinga.com/quote/LYV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Shift4 Payments, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) price target from $93 to $120. Piper Sandler analyst Clarke Jeffries maintained an Overweight rating. Shift4 Payments shares closed at $99.12 on Tuesday. <a href="https://www.benzinga.com/quote/FOUR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Phillip Securities boosted Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) price target from $420 to $485. Phillip Securities analyst Jonathan Wolleben downgraded the stock from Buy to Accumulate. Spotify shares closed at $419.39 on Tuesday. <a href="https://www.benzinga.com/quote/SPOT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic cut Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) price target from $84 to $77. Redburn Atlantic analyst Edward Lewis downgraded the stock from Neutral to Sell. Starbucks shares closed at $98.80 on Tuesday. <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased the price target for MAG Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAG#NYSE">MAG</a>) from $18 to $20. HC Wainwright &amp; Co. analyst Heiko Ihle maintained a Buy rating. MAG Silver shares settled at $15.22 on Tuesday. <a href="https://www.benzinga.com/quote/MAG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group boosted Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) price target from $321 to $365. Evercore ISI Group analyst David Raso downgraded the stock from In-Line to Underperform. Caterpillar shares closed at $393.01 on Tuesday. <a href="https://www.benzinga.com/quote/CAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised the price target for Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) from $120 to $160. Baird analyst Catherine Ramsey maintained an Outperform rating. Natera shares closed at $135.12 on Tuesday. <a href="https://www.benzinga.com/quote/NTRA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham increased Dayforce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) price target from $82 to $95. Needham analyst Scott Berg maintained a Buy rating. Dayforce shares closed at $78.96 on Tuesday. <a href="https://www.benzinga.com/quote/DAY/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41929909/dow-sp-decline-ahead-of-key-inflation-data-tesla-trump-media-slides-fear-index-remains-in-greed-zone">Dow, S&amp;P Decline Ahead Of Key Inflation Data, Tesla, Trump Media Slides: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

FOUR

HRTX

SBUX

SHOP

Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday

CAVA: 18% &#x7C; <a href="https://www.benzinga.com//node/41935163">Cava Group shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 net new restaurant openings outlook and same sales growth.</a>
&nbsp;
NTRA: 25% &#x7C; <a href="https://www.benzinga.com//node/41935174">Natera shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates.</a>
&nbsp;
RIVN: 15% &#x7C; <a href="https://www.benzinga.com//node/41935201">Rivian Automotive shares are trading higher after the company announced a joint venture launch with Volkswagen for a total deal size worth up to $5.8 billion.</a>

Market-Moving News for November 13th

Baird analyst Catherine Ramsey maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Outperform and raises the price target from $120 to $160.

Baird Maintains Outperform on Natera, Raises Price Target to $160

WIIM

Natera shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates.

Guidance

Natera Sees FY24 SG&A $775M-$825M; R&D $375M-$400M' Net Cash Inflows $50M-$75M.

Natera Sees FY24 Revenue $1.61B-$1.64B Vs $1.518B Est

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.58) by 55.17 percent. The company reported quarterly sales of $439.800 million which beat the analyst consensus estimate of $361.450 million by 21.68 percent. This is a 63.92 percent increase over sales of $268.306 million the same period last year.

Earnings Beats

Natera Q3 2024 GAAP EPS $(0.26) Beats $(0.58) Estimate, Sales $439.800M Beat $361.450M Estimate

Wall Street saw the first surge in risk aversion after Donald Trump's election victory last week, as concerns grew over potential tariffs and trade policy shifts spurred by the<a href="https://www.benzinga.com/trading-ideas/movers/24/11/41902202/trumps-china-hawks-rumored-for-top-roles-yuan-hits-3-month-low"> incoming administration's key appointments.</a>
Trump is reportedly considering Sen. Marco Rubio (R-Fla.) for secretary of state and Rep. Mike Waltz (R-Fla.) for national security advisor. Both are vocal hawks on China and NATO, raising concerns of a tougher U.S. stance that could strain key geopolitical and trade relationships.
Adding to the cautious sentiment, investors are bracing for Wednesday's key inflation data release, with economists forecasting the annual rate to hit 2.6% in October.
As of midday trading in New York, none of the major U.S. equity indices posted gains, while small caps underperformed, with the Russell 2000 down 1.5%. Ten out of 11 S&amp;P 500 sectors traded in the red, with consumer staples the only marking tiny gains.
Chinese stocks suffered steep declines, with major U.S.-listed companies falling between 5% and 9% as worries over potential tariffs spooked investors.
The dollar, viewed as a hedge against tariff risk, strengthened, with a currency-weighted index reaching its highest level since May 2024. 
The Japanese yen slipped past 154.7 per dollar, fully erasing gains from the Bank of Japan's August intervention, while the Chinese yuan and the euro also weakened, with the euro falling below $1.06.
Treasury yields climbed, with the 10-year Treasury yield up eight basis points to 4.42%, pushing the popular iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) down 1.2%.
The cryptocurrency market also faced pressure, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) down 1.6%. Gold dropped for a third straight day, weighed down by a stronger dollar and higher Treasury yields, as it struggled to attract safe-haven inflows.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,057.69</td>
<td>-0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,984.47</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,071.38</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,399.25</td>
<td>-1.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:20 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent111224&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.4% to $596.29.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.7% to $440.41.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) inched 0.4% lower to $511.95.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 1.6% to $237.82.</li>
<li>The&nbsp;Consumer Staples Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) outperformed, rising 0.1%. The&nbsp;Materials Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 1.6%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
Stocks moving on earnings reports were: 
<ul>
<li>Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), down 0.5%,</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>), up 26%, </li>
<li>Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>), up 9%, </li>
<li>Live Nation Entertainment Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>), up 4.4%. </li>
</ul>
Companies reporting their results after the close are Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), Occidental Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), Flutter Entertainment plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), Natera Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>). CAVA Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/41909846/trumps-treasury-pick-frontrunner-scott-bessent-could-shift-wall-street-crypto">Trump&#8217;s Treasury Pick Frontrunner Scott Bessent Could Shift Wall Street, Crypto</a></li>
</ul>
Photo: Owlie Productions via Shutterstock

Asia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Large Cap

Commodities

Politics

Global

Economics

Tech

$BTC

iShares Trust Barclays 20+ Year Treasury Bond Fund

Stocks Fall On Tariffs Fears, Dollar Hits 6-Month Peak, Yen Tumbles: What's Driving Markets Tuesday?

BTIG raised the firm's price target on Natera (NTRA) to $185 from $150 and keeps a Buy rating on the shares. The company's Q3 results "knocked it o...

Natera price target raised to $185 from $150 at BTIG

Piper Sandler analyst David Westenberg reiterated a Buy rating on Natera (NTRA – Research Report) today and set a price target of $150.00. The comp...

Natera (NTRA) Receives a Buy from Piper Sandler

Craig-Hallum analyst William Bonello maintained a Buy rating on Natera (NTRA – Research Report) today and set a price target of $157.00. The compan...

Craig-Hallum Remains a Buy on Natera (NTRA)

Morgan Stanley analyst Tejas Savant raised the firm's price target on Natera (NTRA) to $176 from $132 and keeps an Overweight rating on the shares....

Natera price target raised to $176 from $132 at Morgan Stanley

Druckenmiller's Duquesne closes some media holdings, loads into regional banks, among Q3 trades

Life sciences stocks viewed positively at TD Cowen despite post-election weakness

Piper Sandler raised the firm's price target on Natera (NTRA) to $200 from $150 following quarterly results. The firm keeps an Overweight rating on...

Natera price target raised to $200 from $150 at Piper Sandler

JPMorgan's 'Analyst Focus List' – growth, income, value, short ideas

Trump Media saw the largest increase in short interest in October

Goldman's Hedge Fund VIP List: AMZN, VST, CRM, BABA, and more

AAPL

ADPT

AGCO

ALIT

ALRM

AMKR

AMTM

AMZN

ANSS

ARMK

ASND

AVGO

AVTR

BABA

BIRK

BKNG

BRBR

BRKR

CART

CELH

CORT

CORZ

CPNG

CVNA

DAWN

DELL

DKNG

DOCU

ENPH

ENSG

EWTX

EXAS

EXPE

GOOGL

GWRE

HBAN

ILMN

INSM

ISRG

JNPR

KLAC

KVUE

LBRDK

LBTYA

LBTYK

LCID

LEGN

LINE

MDGL

MDXH

MELI

MNDY

MSFT

MYGN

NFLX

NVDA

NWSA

ODFL

OLLI

PACB

PODD

PYPL

ROIV

RVMD

RVTY

SCHW

SIRI

SMAR

SMMT

SNDX

SPGI

SWKS

SWTX

TEVA

TFII

TMUS

TRGP

TVTX

UBER

ULTA

UPST

VERX

VICI

VRNA

VRNS

Comments

Natera

空売り

Natera (NASDAQ:NTRA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル